Corient Private Wealth LP Takes Position in Illumina, Inc. $ILMN

Corient Private Wealth LP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, HoldingsChannel.com reports. The fund purchased 91,197 shares of the life sciences company’s stock, valued at approximately $16,035,000.

Other large investors have also made changes to their positions in the company. Capital World Investors raised its position in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares in the last quarter. BlackRock Inc. bought a new stake in Illumina during the second quarter worth $3,374,423,000. State Street Corp boosted its holdings in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after purchasing an additional 190,324 shares in the last quarter. WCM Investment Management LLC boosted its holdings in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 457,858 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,034,688 shares of company stock valued at $417,970,281. Insiders own 2.90% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $215.59 on Friday. The firm’s fifty day moving average price is $194.05 and its two-hundred day moving average price is $155.60. The stock has a market cap of $32.55 billion, a PE ratio of 40.22, a PEG ratio of 3.20 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the company earned $1.19 EPS. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ILMN shares. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. TD Cowen raised their price objective on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Barclays lifted their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Finally, Guggenheim increased their target price on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $188.40.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.